What are the survival rates for Acute Promyelocytic Leukemia treated with ATRA and ATO?

Acute Promyelocytic Leukemia (APL) is a subtype of acute myeloid leukemia that is highly treatable with a combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). This regimen has become the standard of care for newly diagnosed patients. Survival rates are excellent, with most patients achieving long-term remission and cure.

What the research says

A prospective phase II trial from Japan (FBMTG-APL2017) reported a 3-year overall survival (OS) of 95.0% and disease-free survival (DFS) of 93.6% in 81 newly diagnosed APL patients treated with ATRA and ATO ³. Complete remission was achieved in 95.1% of patients, and molecular remission after consolidation was 99% ³. A landmark phase 3 trial published in the New England Journal of Medicine found 2-year event-free survival of 97% with ATRA-ATO versus 86% with ATRA-chemotherapy in low-to-intermediate risk APL ⁵. Long-term data from MD Anderson Cancer Center estimate 10-year survival rates of ≥80% with ATRA and ATO ⁷. Even in high-risk patients (white blood cell count >10×10⁹/L), the Japanese trial showed 3-year DFS of 80.0% ³. For the rare TTMV::RARA-positive APL, standard ATRA-ATO may be insufficient, but adding venetoclax can achieve molecular remission ¹. In a case of cryptic PML::RARA fusion, ATRA-ATO induction led to complete molecular remission, though relapse occurred after early discontinuation of maintenance ².

What to ask your doctor

• What is my specific risk group (low, intermediate, or high) based on my white blood cell count and other factors?
• Is ATRA plus ATO the recommended treatment for my APL subtype, including any rare genetic variants?
• What are the expected survival rates and remission probabilities for someone with my characteristics?
• How will we monitor for molecular relapse after completing induction and consolidation therapy?
• What side effects should I watch for, such as differentiation syndrome, and how are they managed?